Xenon Pharmaceuticals Inc
XENEXenon Pharmaceuticals Inc. is a biotechnology company focused on developing innovative medicines for neurological and neurological-like disorders. It specializes in using its proprietary platform to identify and develop targeted therapies, with a strong focus on pain, epilepsy, and other neurological conditions. The company employs a deep understanding of ion channels and genetics to advance its pipeline of potential treatments.
Company News
Xenon Pharmaceuticals granted 39,250 share options to five new non-officer employees, with options vesting over four years and an exercise price of $44.61 per share.
Xenon Pharmaceuticals granted 24,200 share options to six new non-officer employees, with an exercise price of $30.54 per share, vesting over four years.
Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units. The share options have an exercise price of $38.28 per common share and vest over four years, while the performance share units will vest based on the achievement of certain predefi...
The epilepsy market is expected to grow due to an increase in disease prevalence and the launch of emerging therapies. The market is segmented into partial epilepsy, chronic focal epilepsy, and drug-resistant epilepsy, with various treatment options and pipeline drugs.
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
